Abatacept Improves GvHD Outcomes Save
The results from a phase 2 clinical trial presented at the American Society of Hematology meeting demonstrated that the drug abatacept was highly effective in managing severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.
Researchers from the Seattle Children's Research Institute showed that adding abatacept to the standard drug regimen for the prevention of GvHD reduced the occurrence of acute, grade III-IV GvHD from 32 to 3 percent in pediatric and adult patients who underwent mismatched unrelated donor stem cell transplants to treat advanced cancer and other blood disorders.
Overall, patients with the abatacept addition experienced improved disease-free duration and and survival compared to those without it.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.